Table III.
Variables Used for the Calculation of R-Values
| Imax a (μM) | Fa b | Dosec (mg) | Fu d | |
|---|---|---|---|---|
| Cyclosporin A | 1.37 | 0.5 | 886.2 | 0.1 |
| Gemfibrozil | 99.9 | 0.98 | 600 | 0.05 |
| Fenofibrate | 29.8 | 0.81 | 300 | 0.01 |
| Lopinavir | 15.4 | na | 400 | 0.02 |
| Atazanavir | 4.47 | 0.68 | 400 | 0.14 |
| Amprenavire | 11.2 | 0.9 | 600 | 0.1 |
na not available
aMaximum systemic plasma concentration of the inhibitor, obtained from (23–28)
bFraction of the inhibitor dose absorbed. Here, the maximum oral bioavailability, as obtained from (23–25), is displayed
cInhibitor dose for each occasion on which a dose was given, obtained from (23–28)
dFraction of the inhibitor that is unbound, obtained from (3,23,24)
eImax and the dose, recalculated from Fosamprenavir data